Replies to post #15771 on Relief Therapeutics Holding AG (RLFTF)

[Charliebee]

great DD indeed :)

https://www.reddit.com/r/investing/comments/ihjz24/rlftf_the_most_promising_covid19_stock_drug/


BUY AND HOLD!

[Charliebee]

I am sure we are VERY NEAR to see some spectacular RLF-news....exciting times ahead of us.

[The Whale]

Share Price Target

While it is difficult to determine a Share Price for a Stock which this Potential, my personal calculations put the potential between 5-20$. Analysis see the intermediate Share Price target at 18$ which would be a 3600% increase of the current Price. 

[BillionBux]

Great DD. Here is the text version from the link you provided

https://www.reddit.com/r/investing/comments/ihjz24/rlftf_the_most_promising_covid19_stock_drug/

RLFTF - the most promising COVID-19 Stock / Drug?

This Post intends to give an overview over the ticker RLFTF, it is divided in different sections to give a holistic overview over RLFTF. RLFTF is a Drug Development Company registered at the Swiss Stock Exchange RLF.SW and US OTC Ticker RLFTF.

RLFTF's patented drug RLF-100^(TM)(Aviptadil/VIP) has a FDA Fast Track designation and is in two Clinical Trials and a FDA Intermediate Expanded Access Program. Preliminary data show a mortality reduction of over 90% in the most critical COVID-19 ICU Patients.^(3)

**Clinical Data and Mechanism of Action - why this is the best COVID-19 drug.**

RLF-100(Aviptadil/VIP) has a 30 year research history and is already Approved by some Countries for other Indications (UK Approved for Errectile Dysfunction and EU Orphan drug status for Sarcoidosis treatment \*EU designation (EU/3/07/473)), it is already known to be a safe drug with minimal side-effects. ^(5,6)

*Mechanism Of Action*

1. RLF-100 inhibits the SARS-COV-2(COVID19) Virus from replicating itself by blocking the respective receptors. **It is the only known Drug** so far that **prevents the Virus from replicating**(spreading), it act's preventive and not just symptomatic. ^(1)
2. RLF-100 prevents and/or stops the Zytokine Storm, is highly anti-inflamantory and acts on RANTES (CCL5) - in almost the same way that e.g. CYDY's LL drug does.^(2)
3. RLF-100 is a natural peptide produced and used by the body to protect & heal the lung and to improve blood oxygenation. Severe CASES of COVID-19 have shown low levels of exactly this Peptide.^(3)

*Clinical Data*

Currently there are 2 Clinical Trials underway and a FDA Intermediate Expanded Access Program.

1. Phase 2/3 Trial, IV RLF-100 for Critical COVID-19 Patients, Estimated completion in September 2020 [https://clinicaltrials.gov/ct2/show/NCT04311697](https://clinicaltrials.gov/ct2/show/NCT04311697)
2. FDA granted IND for Clinical Trial of RLF-100 in inhaled version with the goal to provide a **preventive treatment at home** to prevent a moderate/severe COVID-19 infection.^(4) Estimated completion in November [https://clinicaltrials.gov/ct2/show/NCT04360096](https://clinicaltrials.gov/ct2/show/NCT04360096)
3. FDA Intermediate Population Expanded Access of RLF-100, Expanded Access Program for cases too critical to be part of the above studies. In this EAP aims to treat the most critical COVID-19 Patient. [https://clinicaltrials.gov/ct2/show/NCT04453839](https://clinicaltrials.gov/ct2/show/NCT04453839)

All currently available Clinical Data regarding COVID-19 is from the Expanded Access. The first 21 Patients showed a Rapid recovery and a mortality reduction of over 90%. This patients consist out of the worst case COVID-19 cases like patients with combined double lung transplant rejection and severe COVID-19 infections. ^(3)

*Summary:*

RLF-100 blocks the COVID-19 Virus, prevents a zytokine storm, heals the lungs and improves blood oxygenation with a mortality reduction of over 90% in the most severe cases.

*Further possible indications*

Possible further indications for RLF-100 are almost all lung affecting diseases, as RLF-100 protects and heals the lungs.

Further RLF-100 acts on RANTES(CCL5) and could be indicated for treatment of HIV, Cancer and other RANTES specific diseases after further studies.

**Current Demand / Demand for Expanded Access**

\- On behalf of Relief Therapeutics, NeuroRX is currently fielding multiple requests from representatives of health ministries, who would like to access RLF-100 for their countries. ^(7)

\- There is currently a high volume of requests for Expanded Access from US licensed physicians ^(8)

**FDA Fast Track & NeuroRX Partnership**

RLFTF has a FDA Fast Track designation for the RLF-100 Drug 1 all clinical trials and studies are conducted by Relief Therapeutics partner NeuroRX, a privately held US Company. Relief Therapeutics own all rights on RLF-100 and pays NeuroRX to conduct the trials. ^(6)

**Share Price Target**

While it is difficult to determine a Share Price for a Stock which this Potential, my personal calculations put the potential between 5-20$. Analysis see the intermediate Share Price target at 18$ which would be a 3600% increase of the current Price. `9`

**Catalysts in the near Future**

In the Upcoming Days we expect an announcement of a Partnership with a large drug distribution and logistics Company. ^(10)

1. A Board member of RLFTF saidduring an interview that by October they will be ready to deliver treatment to 100'000 patients. ^(10)
2. Study Results of the Phase 2/3 Study are due in September. Judged by the Expanded Access data, which treats more severe Cases than in the Study, the results are expected to be very good. ^(10)
3. It is expected that the Data Monitoring Committee might Stop the study and recommend an approval to the FDA, so that Patients from the Placebo control group can be treated as well.^(10)

**Stock Exchange, Markets and Regulatory Specifics**

RLFTF is registered as RLF.SW at the Swiss Stock Exchange and is subject to swiss exchange law's and regulations. All Management Transactions and Transactions of Significant Shareholders have to be Published according to the Swiss Exchange Regulations.

Publishing of (Corporate) News is only allowed off Market (at least 90 minutes prior to Market opening) if News is published during the Market hours, trading will be suspended for some time. There is little chance with this stock for a late "jump-on" once a big catalyst is released, as it will be off-market.

In the US RLFTF is a OTC Traded Stock. RLFTF just filed a OTCQB Application and will therefor also be regulated by the SEC in the future, though i fell the Swiss Regulation is stricter anyway.

**Information about Market Cap, Outstanding Shares and Expected Earnings.**

There was a very comprehensive interview by a Swiss Investment Newspaper covering the Above topics, please check out [https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478](https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478) , it contains almost everything we want to know at this Point.

**Disclaimer**

I follow the clinical development of RLF-100 since the outbreak of SARS-COV-2 and i'm invested since early spring, i see myself as a long term investor. My primary investment motivation is that, after extensive reasearch over months, i believe in the potential of this drug. Please do your own due diligence prior to investment and let me know if you would like to have more information included in this Post, i'll try to update it accordingly.

1 [https://www.prnewswire.co.uk/news-releases/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-892685658.html](https://www.prnewswire.co.uk/news-releases/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-892685658.html)

2 [https://www.businesswire.com/news/home/20200607005050/en/Relief-Therapeutics-NeuroRx-Expand-Clinical-Trial-RLF-100](https://www.businesswire.com/news/home/20200607005050/en/Relief-Therapeutics-NeuroRx-Expand-Clinical-Trial-RLF-100)

3 [https://papers.ssrn.com/sol3/papers.cfm?abstract\_id=3665228](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228)

4 [https://www.prnewswire.co.uk/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure-874341601.html](https://www.prnewswire.co.uk/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure-874341601.html)

5 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738270/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738270/)

6 [https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478](https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478)

7 [https://www.neurorxpharma.com/our-services/non-us-country-rep/](https://www.neurorxpharma.com/our-services/non-us-country-rep/)

8 [https://www.neurorxpharma.com/our-services/usa-licensed-physicians/](https://www.neurorxpharma.com/our-services/usa-licensed-physicians/)

9 [https://seekingalpha.com/article/4367483-relief-therapeutics-discovers-promising-covidminus-19-killer](https://seekingalpha.com/article/4367483-relief-therapeutics-discovers-promising-covidminus-19-killer)

10 [

)